{"id":457087,"date":"2019-12-17T06:34:01","date_gmt":"2019-12-17T06:34:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=457087"},"modified":"2019-12-17T06:34:01","modified_gmt":"2019-12-17T06:34:01","slug":"gastrointestinal-drugs-market-share-analysis-growth-opportunity-industry-size-top-key-players-regional-demand-overview-trends-and-outlook-2023","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/gastrointestinal-drugs-market-share-analysis-growth-opportunity-industry-size-top-key-players-regional-demand-overview-trends-and-outlook-2023_457087.html","title":{"rendered":"Gastrointestinal Drugs Market Share Analysis, Growth Opportunity, Industry Size, Top Key Players, Regional Demand Overview, Trends and Outlook 2023"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1576581455.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Gastrointestinal Drugs Market Share Analysis, Growth Opportunity, Industry Size, Top Key Players, Regional Demand Overview, Trends and Outlook 2023\" src=\"https:\/\/www.abnewswire.com\/uploads\/1576581455.jpeg\" alt=\"Gastrointestinal Drugs Market Share Analysis, Growth Opportunity, Industry Size, Top Key Players, Regional Demand Overview, Trends and Outlook 2023\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Gastrointestinal Drugs Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Gastrointestinal Drugs Market Analysis By Drug Class (Acid Neutralizers, Laxatives &#038; Antidiarrheal, Anti-Emetics, Antiulcer), By Type Of Disease (Esophagus Diseases, Stomach Diseases, Intestinal Diseases, Rectum Diseases) \u2013 Asia Pacific Industry Forecast till 2023\n<\/div>\n<p>Asia Pacific Gastrointestinal Drugs Market Share Is Expected to Grow at a CAGR of 6.1% During The Forecast Period 2017-2023.<\/p>\n<p><strong>Market Overview<\/strong><\/p>\n<p>Gastrointestinal (GI) diseases affects stomach, large intestine and rectum, small intestine, esophagus, liver, gallbladder, and pancreas. The symptoms of GI diseases are heartburn, indigestion, bloating, constipation, and many more. The diseases of gastrointestinal have become common in the people across world.&nbsp; Gastrointestinal diseases are caused by various reasons such as acid reflux, heartburn, indigestion, nausea and vomiting, peptic ulcer disease, abdominal pain syndrome, biliary tract disorders, gallbladder disorders, and gallstone pancreatitis.<\/p>\n<p><strong><em>Avail a Free Sample PDF@ <a rel=\"nofollow\" href=\"https:\/\/www.marketresearchfuture.com\/sample_request\/633\">https:\/\/www.marketresearchfuture.com\/sample_request\/633<\/a> <\/em><\/strong><\/p>\n<p><strong>Key Findings<\/strong><\/p>\n<ul>\n<li>The Asia gastrointestinal drugs market is expected to reach USD 20,772.4 million by 2023 at a CAGR of 6.1%<\/li>\n<li>Acid neutralizers segment accounted for the largest market share with 33.3% of the Asia gastrointestinal drug market, by drug types in 2016<\/li>\n<li>In 2016, Esophagus diseases segment accounted for the major share of the market as it was the most widely occurring GI disease. The Asia esophagus diseases market by type of diseases is expected to reach USD 7,427.6 million by 2023, growing at a CAGR of 6.32% from 2017 to 2023<\/li>\n<li>India is expected to be the fastest growing market at a CAGR of 6.60% during the forecast period<\/li>\n<\/ul>\n<p>Some of the leading key players in this market are listed below-<\/p>\n<p>Abbott<\/p>\n<p>Allergan Plc<\/p>\n<p>AstraZeneca<\/p>\n<p>Eli lilly Company<\/p>\n<p>F. Hoffmann-La Roche Ltd<\/p>\n<p>GlaxoSmithKline plc<\/p>\n<p>Pfizer Inc<\/p>\n<p>Valeant Pharmaceuticals<\/p>\n<p>and others.<\/p>\n<p><strong>Gastrointestinal Drugs Market Segmentation:<\/strong><\/p>\n<p>The gastrointestinal drugs market is segmented on the basis of drug class and type of disease.<\/p>\n<p>On the basis of drug class, it is segmented into acid neutralizers, laxatives &amp; antidiarrheal, antiemetics, antiulcer, and others.<\/p>\n<p>On the basis of type of disease, it is segmented into esophagus diseases, stomach diseases, intestinal diseases, rectum diseases, and others.<\/p>\n<p><strong>MARKET DYNAMICS<\/strong><\/p>\n<p>1 Introduction<\/p>\n<p>2 Drivers<\/p>\n<p>2.1 Increasing Prevalence Of Gastrointestinal Diseases<\/p>\n<p>2.2 Increasing Investments And Funding In The Field Of Life Science Research<\/p>\n<p>2.3 Increasing Awareness Among The People<\/p>\n<p>2.4 Growing Geriatric Population<\/p>\n<p>2.5 Changing Reimbursement Policies<\/p>\n<p>3 Restraints<\/p>\n<p>3.1 Presence Of Misbranded And Spurious Drugs<\/p>\n<p>4 Opportunities<\/p>\n<p>4.1 Development Of New Drugs<\/p>\n<p><strong>Browse Complete Premium Research Details@ <a rel=\"nofollow\" href=\"https:\/\/www.marketresearchfuture.com\/reports\/asia-pacific-gastrointestinal-drugs-market-633\">https:\/\/www.marketresearchfuture.com\/reports\/asia-pacific-gastrointestinal-drugs-market-633<\/a> <\/strong><\/p>\n<p>To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East &amp; Africa.<\/p>\n<p>To provide country level analysis of the market with respect to the current market size and future prospective<\/p>\n<p>To provide country level analysis of the market for segments by drug class, and its sub-segments.<\/p>\n<p>To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market<\/p>\n<p>To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Contraceptive Pills market.<\/p>\n<p>Pfizer Inc. has introduced SAYANA, first injectable contraceptive in UK which can be self-administered.<\/p>\n<p>Teva Pharmaceutical Industries Ltd. has launched Beyaz which is a generic contraceptive drug. It is one of the most successful product of the company and in 2016 it has annual sales of approximately $133 million in the US.<\/p>\n<p><em>Get an Amazing Discount@ <a rel=\"nofollow\" href=\"https:\/\/www.marketresearchfuture.com\/check-discount\/2122\">https:\/\/www.marketresearchfuture.com\/check-discount\/2122<\/a> <\/em><\/p>\n<p><strong>INTENDED AUDIENCE<\/strong><\/p>\n<ul>\n<li>Contraceptive pills suppliers<\/li>\n<li>Contraceptive pill manufacturers<\/li>\n<li>Pharmaceutical Companies<\/li>\n<li>Research and Development (R&amp;D) Companies<\/li>\n<li>Government Research Laboratories<\/li>\n<li>Government and Independent Regulatory Authorities<\/li>\n<li>Medical Research Institutes<\/li>\n<\/ul>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/marketresearchfuture.com_36734.html\" rel=\"nofollow\">Market Research Future<\/a><br \/><strong>Contact Person:<\/strong> Abhishek Sawant<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=gastrointestinal-drugs-market-share-analysis-growth-opportunity-industry-size-top-key-players-regional-demand-overview-trends-and-outlook-2023\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +1 646 845 9312<br \/><strong>Address:<\/strong>Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar  <br \/><strong>City:<\/strong> Pune<br \/><strong>State:<\/strong> Maharashtra<br \/><strong>Country:<\/strong> India<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.marketresearchfuture.com\/reports\/asia-pacific-gastrointestinal-drugs-market-633\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.marketresearchfuture.com\/reports\/asia-pacific-gastrointestinal-drugs-market-633<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.marketresearchfuture.com\/reports\/asia-pacific-gastrointestinal-drugs-market-633\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=gastrointestinal-drugs-market-share-analysis-growth-opportunity-industry-size-top-key-players-regional-demand-overview-trends-and-outlook-2023\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gastrointestinal Drugs Market Gastrointestinal Drugs Market Analysis By Drug Class (Acid Neutralizers, Laxatives &#038; Antidiarrheal, Anti-Emetics, Antiulcer), By Type Of Disease (Esophagus Diseases, Stomach Diseases, Intestinal Diseases, Rectum Diseases) \u2013 Asia Pacific Industry Forecast till 2023 Asia Pacific Gastrointestinal Drugs &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/gastrointestinal-drugs-market-share-analysis-growth-opportunity-industry-size-top-key-players-regional-demand-overview-trends-and-outlook-2023_457087.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,438,402,405,406],"tags":[],"class_list":["post-457087","post","type-post","status-publish","format-standard","hentry","category-Business","category-Fitness","category-Food-Beverage","category-Health-Medicine","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/457087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=457087"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/457087\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=457087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=457087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=457087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}